{
  "trial_id": "NCT01035229",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, race, ECOG performance status, Child-Pugh score, prior sorafenib treatment duration, reason for sorafenib discontinuation (progression or intolerance), prior local therapy, prior hormonal therapy, prior systemic chemotherapy, presence of active bleeding, prior mTOR inhibitor therapy, prior organ transplantation.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Race/Ethnicity",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Weight",
        "Height",
        "BMI"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "Child-Pugh score",
        "prior sorafenib treatment duration",
        "reason for sorafenib discontinuation (progression or intolerance)",
        "prior local therapy",
        "prior hormonal therapy",
        "prior systemic chemotherapy",
        "presence of active bleeding",
        "prior mTOR inhibitor therapy",
        "prior organ transplantation"
      ]
    },
    "processed-gen-response": "Age, gender, race, ECOG performance status, Child-Pugh score, prior sorafenib treatment duration, reason for sorafenib discontinuation (progression or intolerance), prior local therapy, prior hormonal therapy, prior systemic chemotherapy, presence of active bleeding, prior mTOR inhibitor therapy, prior organ transplantation."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG performance status, Child-Pugh score, Prior systemic treatment, Duration of prior sorafenib treatment, Reason for sorafenib discontinuation, Baseline liver function tests, Baseline alpha-fetoprotein levels, Baseline tumor burden,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Weight",
        "Height",
        "BMI"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG performance status",
        "Child-Pugh score",
        "Prior systemic treatment",
        "Duration of prior sorafenib treatment",
        "Reason for sorafenib discontinuation",
        "Baseline liver function tests",
        "Baseline alpha-fetoprotein levels",
        "Baseline tumor burden"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG performance status, Child-Pugh score, Prior systemic treatment, Duration of prior sorafenib treatment, Reason for sorafenib discontinuation, Baseline liver function tests, Baseline alpha-fetoprotein levels, Baseline tumor burden"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Child-Pugh Score, Prior Sorafenib Treatment, Prior Systemic Chemotherapy, Hepatocellular Carcinoma Diagnosis Duration,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Weight",
        "Height",
        "BMI"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG Performance Status",
        "Child-Pugh Score",
        "Prior Sorafenib Treatment",
        "Prior Systemic Chemotherapy",
        "Hepatocellular Carcinoma Diagnosis Duration"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Child-Pugh Score, Prior Sorafenib Treatment, Prior Systemic Chemotherapy, Hepatocellular Carcinoma Diagnosis Duration"
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, Child-Pugh score, liver function tests (e.g., bilirubin, albumin, INR), prior sorafenib treatment duration and dose, number of prior systemic chemotherapy regimens, presence of metastases, tumor size and location, alpha-fetoprotein (AFP) levels, liver cirrhosis status, comorbidities (e.g., diabetes, hypertension).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race/Ethnicity",
          "race"
        ],
        [
          "Race/Ethnicity",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Weight",
        "Height",
        "BMI"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "Child-Pugh score",
        "liver function tests (e.g., bilirubin, albumin, INR)",
        "prior sorafenib treatment duration and dose",
        "number of prior systemic chemotherapy regimens",
        "presence of metastases",
        "tumor size and location",
        "alpha-fetoprotein (AFP) levels",
        "liver cirrhosis status",
        "comorbidities (e.g., diabetes, hypertension)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, ECOG performance status, Child-Pugh score, liver function tests (e.g., bilirubin, albumin, INR), prior sorafenib treatment duration and dose, number of prior systemic chemotherapy regimens, presence of metastases, tumor size and location, alpha-fetoprotein (AFP) levels, liver cirrhosis status, comorbidities (e.g., diabetes, hypertension)."
  }
}